Clinical trial

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

NCT04695925

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-03-29

PhasePHASE3

Study timeline

Study start (actual)2021-03-29Date precision: day

Registry last updated2025-10-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Carcinomaunresolved

EGFR Gene Mutationunresolved

Interventions

OsimertinibDRUG · verified · RxNorm: osimertinib

PemetrexedDRUG · verified · RxNorm: pemetrexed

CarboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

Li Zhang, MDlead sponsor

Cancer Hospital of Guangxi Medical Universitycollaborator

First People's Hospital of Foshancollaborator

Henan Cancer Hospitalcollaborator

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04695925 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.